Brand Reference: Cymbalta
| Metric | Verified Benchmark | Source |
|---|---|---|
| Duloxetine Delayed-Release Enteric Pellets RxNorm Concept ID | 72625 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0920 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $68.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.60 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $8.40 / mo | 33 Zero-PHI Verified Patient Logs |
Maintains a balanced ~10:1 SERT-to-NET binding ratio starting at 30–60 mg, engaging both limbic affective circuits and descending bulbospinal noradrenergic inhibitory pathways in the dorsal horn to attenuate fibromyalgia and diabetic neuropathic pain.
Across 33 community cost disclosures for Duloxetine Delayed-Release Enteric Pellets (Cymbalta), cash buyers routing around $68.00 retail markups capture a 90% discount ($6.60/mo benchmark vs $0.0920 NADAC acquisition).
Following administration (20–30 mg DR PO once daily starter), Duloxetine Delayed-Release Enteric Pellets achieves 50% oral (reduced 30% in smokers via CYP1A2 induction) bioavailability and 1–2 weeks neuropathic pain softening; 3–4 weeks gad/mdd onset, governed by a 12 hours (acid-labile; enteric pellets must never be crushed) terminal half-life through hepatic cyp1a2 and cyp2d6 ring oxidation.
Before initiating Duloxetine Delayed-Release Enteric Pellets at 20–30 mg DR PO once daily starter, clinical safety checklists rule out heavy chronic alcohol abuse or hepatic insufficiency (hepatotoxicity risk); potent cyp1a2 fluvoxamine/ciprofloxacin; maoi. Logged tolerability patterns center on taper sensitivity (28% of reports), first-week nausea (25% of reports), hyperhidrosis (18% of reports).
Across 33 verified cash-pay logs, Duloxetine Delayed-Release Enteric Pellets achieves a 81.60% Worth-It rating with out-of-pocket spend averaging $8.40/mo versus $68.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 20–30 mg DR PO once daily starter for Duloxetine Delayed-Release Enteric Pellets; monthly out-of-pocket dropped to $5.81 compared with $68.00 retail.
Completed 10 weeks on Duloxetine Delayed-Release Enteric Pellets (60 mg DR PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 20–30 mg DR PO once daily starter Duloxetine Delayed-Release Enteric Pellets sourced via TeleMed ($7.66/mo cash pay without insurance prior authorization).